Induction immunosuppression in high-risk kidney transplant recipients; beauty and the beast

J Buttigieg, JULIE-MICHELLE BRIDSON, A Sharma, A Halawa

Research output: Contribution to journalArticle (journal)peer-review

7 Citations (Scopus)


Kidney transplant remains the best type of renal replacement therapy in most patients with end-stage kidney disease, even in those with high immunologic risk. Immunosuppression in these patients is regarded as more complex, owing to the higher risk of both acute and chronic rejection. The advent of induction immunosuppression has resulted in a lower incidence of acute rejection and consequently improved short-term patient and allograft outcomes. Indeed, the use of these agents, especially in high-risk recipients, has become standard of care at most transplant centers. Transplant physicians are constantly faced with the challenge of estimating the recipients' immunologic risk and tailoring their immunosuppression accordingly. This review article aims to provide an up-to-date evaluation of the various studies available, which investigated the use of induction agents in kidney transplant, specifically in high-risk recipients. It evaluates the use of the most frequently used polyclonal antibody (rabbit antithymocyte globulin) versus the less commonly used monoclonal antibody alemtuzumab, superseded agents such as muromonab-CD3, and potentially emerging agents such as rituximab, bortezomib, and eculizumab. With this systematic review, we hope to inform the scientific community and facilitate this controversial decision through the implementation of robust scientific evidence.
Original languageEnglish
Pages (from-to)367-376
JournalExperimental and Clinical Transplantation
Issue number4
Publication statusPublished - 31 Aug 2016


Dive into the research topics of 'Induction immunosuppression in high-risk kidney transplant recipients; beauty and the beast'. Together they form a unique fingerprint.

Cite this